Navigation Links
Celsion Reports Third Quarter 2010 Financial Results and Provides Business Update
Date:11/15/2010

COLUMBIA, Md., Nov. 15, 2010 /PRNewswire-FirstCall/ -- Celsion Corporation (Nasdaq: CLSN), a biotechnology drug development company, today announced financial results for the third quarter and nine months ended September 30, 2010 and addressed the progress of its clinical trials of ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin for the treatment of hepatocellular carcinoma (HCC), commonly referred to as primary liver cancer.  ThermoDox® is currently being evaluated under a Special Protocol Assessment with the FDA in a 600 patient pivotal Phase III trial (the HEAT study) in patients with non-resectable primary liver cancer and in a Phase I/II trial for patients with recurrent chest wall breast cancer.   The HEAT study has been designated as a Priority Trial for liver cancer by the National Institutes of Health.

"We are approaching 80% completion of patient enrollment into our Phase III primary liver cancer HEAT study of ThermoDox®.  Together with our Special Protocol Assessment for the HEAT study, Celsion received Fast Track Designation from the FDA providing us with the opportunity to file our New Drug Application on a rolling basis.  We now have an efficient clinical and regulatory pathway for commercialization of ThermoDox®," said Michael Tardugno, Celsion's President and Chief Executive Officer.Financial Results For the third quarter ended September 30, 2010, Celsion reported a net loss from operations of $5.2 million compared to a net loss from operations of $4.7 million for the same period of 2009.  For the first nine months of 2010, net cash used in operations was $10.6 million.  Celsion reported a net loss from operations of $14.2 million for the first nine months of 2010 compared to a net loss from operations of $13.2 million for the same period of 2009.  In the third quart
'/>"/>

SOURCE Celsion Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Celsion Announces Date and Time Change for Third Quarter 2010 Financial Results Conference Call to Monday, November 15, 2010
2. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
3. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
4. Par Pharmaceutical Reports Second Quarter 2008 Results
5. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
6. Pharmos Corporation Reports 2008 Second Quarter Results
7. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
8. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
9. BMP Sunstone Reports Second Quarter 2008 Financial Results
10. ULURU Inc. Reports Second Quarter 2008 Financial Results
11. Immtech Reports Fiscal First Quarter 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015   SurePure, Inc ... photopurification, announced today that the Company has completed ... continued trading of SurePure ("SURP") securities on OTCQB, ... for entrepreneurial and development stage companies. ... standards and eligibility requirements designed to improve marketplace ...
(Date:3/27/2015)... 27, 2015  CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... commercial focus on China , today ... ended December 31, 2014.  The Company ... per share, for the three months ended December 31, ...
(Date:3/26/2015)... TORONTO , March 26, 2015 /PRNewswire/ - SQI ... SQIDF) announced that after dealing with certain matters, including ... of shareholders held on March 26, 2015 (the "Meeting") ... until April 8, 2015 at 11:00 a.m. ( ... Meeting has been changed from that previous disclosed. The ...
(Date:3/26/2015)... 2015 Neogen Corporation (NASDAQ: NEOG ) ... quarter of fiscal 2015, which ended Feb. 28, increased ... $6,575,000. Earnings per share in the current quarter were ... net income increased 17% over prior year to $24,142,000, ... per share, for the same period a year ago. ...
Breaking Biology Technology:SurePure Completes Verification and Approved for Trading on the OTCQB Marketplace 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6SQI Diagnostics Inc. Announces Adjournment of Meeting 2Neogen reports 13% increase in net income 2Neogen reports 13% increase in net income 3Neogen reports 13% increase in net income 4Neogen reports 13% increase in net income 5Neogen reports 13% increase in net income 6Neogen reports 13% increase in net income 7Neogen reports 13% increase in net income 8
... March 11 Indevus,Pharmaceuticals, Inc. (Nasdaq: IDEV ) ... and Company 28th Annual Health Care Conference, on,Tuesday, March ... being held in,Boston, Massachusetts. The presentation will be web ... section of the Indevus website at, http://www.indevus.com ., ...
... Lett, CEO of The,BioAnalytics Group LLC and Ned ... Tucson Symposium on March 12-13, 2008. The,symposium, subtitled, ... Diagnostics," will be attended by hundreds of,scientists and ... Dr. Lett,s invited presentation will focus on ...
... France, March 11 Transgene,(Euronext Paris: FR0005175080) announces ... and outlook for 2008., "2007 was a ... the signing of a partnership agreement with Roche ... of diseases caused by the,HPV virus, and the ...
Cached Biology Technology:Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference 2Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference 3BioAnalytics Group CEO, Senior Scientist to Present at Tucson Symposium March 12-13 2Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 2Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 3Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 4Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 5Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 6Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 7Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 8Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 9Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 10Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 11Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 12
(Date:3/17/2015)... , March 17, 2015 ... company specializing in clinical study management systems, is ... in attendance at ARENA,s Outsourcing in Clinical Trials ... This event provides an excellent forum for MedNet ... flexible and affordable software-as-a-service (SaaS) eClinical technology platform. ...
(Date:3/12/2015)... FAIRFAX, Va. , March 12, 2015 ... company and a member of the Texas Instruments Design ... Chandrababu Naidu has demonstrated its IriShield USB MK2120U ... iris scanning facility for pension distribution. ... and assembled to be marketed in India ...
(Date:3/11/2015)... Mar. 11, 2015 Research and Markets ... "Access Control Market by Product, Application & By ... report to their offering. , This report ... reach $10.4 billion by 2020, with an estimated CAGR ... covers the products types such as contact cards & ...
Breaking Biology News(10 mins):Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 3Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2
... planarian possesses an amazing ability to regenerate lost body parts. ... a complete planarian. The flatworm relies upon a population of ... light on how planarians maintain these stem cells throughout their ... issue of the journal Developmental Cell, scientists show that a ...
... By applying electrical currents across the heads of people while ... vestibular system helps us maintain upright posture; at the same ... in a way that allowed a person who was walking ... balance being affected. The findings are reported by Richard Fitzpatrick ...
... of us are familiar with the winding staircase image of ... But few of us realize just how tightly that famous ... a single molecule of human DNA extends more than three ... cell, that same molecule measures about one millionth of an ...
Cached Biology News:Scientists identify gene involved in stem cell self-renewal in planaria 2Stimulation of the semicircular canals can artificially control human walking and balance 2Surprise finding for stretched DNA 2Surprise finding for stretched DNA 3
Mouse monoclonal antibody raised against a partial recombinant DENR. NCBI Entrez Gene ID = DENR...
Mouse monoclonal antibody raised against a partial recombinant CRKRS. NCBI Entrez Gene ID = CRKRS...
... The BD PhosFlow Perm/Wash Buffer I can ... modified signaling proteins to permeabilize cells and ... cell wash buffer. Because saponin-mediated cell permeabilization ... to keep the cells in the presence ...
Mouse monoclonal antibody raised against a full length recombinant GPT. NCBI Entrez Gene ID = GPT...
Biology Products: